Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
REGULATORY
MHLW to Fund Development of Kowa’s Ivermectin for COVID-19
The Ministry of Health, Labor and Welfare (MHLW) said on March 4 that it will provide funding to Kowa’s ivermectin under its support project for the commercialization of COVID-19 therapeutics.Kowa was the only company that raised a hand to the…
To read the full story
Related Article
- Ivermectin Fails in Investigator-Led COVID Trial Too
October 3, 2022
- Ivermectin Misses Goal in PIII COVID-19 Trial: Kowa
September 27, 2022
- Ivermectin Shows Antiviral Effects against Omicron: Kowa
February 1, 2022
- Ivermectin COVID-19 Trial Needed Because Evidence Is Lacking, Kowa Says as It Aims for PIII Wrap-Up in November
October 11, 2021
- Ivermectin to Enter 1st Company-Sponsored COVID-19 Trial in Japan
July 2, 2021
REGULATORY
- Generic Dispensing Rates Spike on New LLP Coverage Rule: Survey
April 11, 2025
- 250 LDP Lawmakers Sign Petition for Revisiting Budget Cap, Off-Year Cuts
April 11, 2025
- MHLW on Alert for Potential Tariffs on Osteomalacia, Schizophrenia Meds
April 11, 2025
- Nippon Ishin Co-Leader Shows Understanding of Off-Year Price Revisions
April 11, 2025
- Clinical Trial Matching Websites Do Not Violate Ad Regulations in PMD Act: MHLW
April 10, 2025
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…